II-01 Emilie Schindler
Comparison of item response theory and classical test theory for power/sample size for questionnaire data with various degrees of variability in items' discrimination parameters
Wednesday 15:15-16:40 |
II-02 Jan-Frederik Schlender
Application of an elderly PBPK model to specify age-dependent changes of active processes
Wednesday 15:15-16:40 |
II-03 Henning Schmidt
SBPOP/mPD: Informing dose-concentration-response relationships - Application to study design and information generation based on competitor data
Wednesday 15:15-16:40 |
II-04 Rik Schoemaker
PK/PD modeling of brivaracetam in epilepsy using daily seizure counts
Wednesday 15:15-16:40 |
II-05 Johannes Schropp
Distributed transit compartments for arbitrary lifespan distributions in aging populations
Wednesday 15:15-16:40 |
II-06 Mark Sellors
Reproducible Analysis Environments for Pharmacometric modelling and simulation.
Wednesday 15:15-16:40 |
II-07 Marina Senek
Population pharmacokinetic modelling of Levodopa/Carbidopa Microtablets versus standard formulations of Levodopa/Benserazide and Levodopa/Carbidopa
Wednesday 15:15-16:40 |
II-08 Kok-Yong Seng
Evaluating Ethnicity Differences in the Effect of Ritonavir, Ketoconazole and Rifampicin on Cytochrome P450 3A Induction and Inhibition in the Asian and Western Populations
Wednesday 15:15-16:40 |
II-09 Seonghae Yoon
Population pharmacokinetics/pharmacodynamics modeling of uric acid formation after xanthine oxidase inhibitor administrations
Wednesday 15:15-16:40 |
II-10 Maria Sfouni
Prediction of subtherapeutic tigecycline plasma levels by model-based Bayesian individualization
Wednesday 15:15-16:40 |
II-11 Siti Maisharah Sheikh Ghadzi
Disease progression in the integrated glucose-insulin model in subjects with impaired glucose tolerance
Wednesday 15:15-16:40 |
II-12 Yucheng Sheng
Development of a New Mixed Poisson-Gaussian Model for Count Data from Rodent Brief-Access Taste Aversion Experiments
Wednesday 15:15-16:40 |
II-14 Hanna Silber Baumann
Support phase II dose selection of a novel dual GIP/GLP-1agonist using a population PKPD model developed on phase I data
Wednesday 15:15-16:40 |
II-15 Giovanni Smania
Model-based comparison of alternative study designs in paediatric trials
Wednesday 15:15-16:40 |
II-16 Byungjeong Song
Application of simplified-ACAT model for specific angiotensin receptor blocker in rats to human
Wednesday 15:15-16:40 |
II-17 Ivy Song
Use of a Viral Dynamic Model to Evaluate Potential Dolutegravir Dosing Regimens in HIV-1 Patients with Resistance to Raltegravir and Elvitegravir
Wednesday 15:15-16:40 |
II-18 Elena Soto
Model informed drug discovery and development of novel treatments for hyperuricemia: from systems pharmacology to mechanistic PK/PD
Wednesday 15:15-16:40 |
II-19 Rujia Xie
Relationship between the Dose of Urate Lowering Therapies and Serum Uric Acid in Healthy Volunteers and Gout Patients: A Model Based Meta-Analysis (MBMA)
Wednesday 15:15-16:40 |
II-20 Marios Spanakis
Application of Simcyp® simulator platform for the assessment of the pharmacokinetic profile of Gd-DOTA regarding its disposition in brain tumors lesions with different vasculature
Wednesday 15:15-16:40 |
II-21 Emmanouil G. Spanakis
MyHealthAvatar platform: matching real life patients with the generated virtual profiles from in silico clinical trials
Wednesday 15:15-16:40 |
II-22 Claudia Stötzel
A Markov Chain Monte Carlo Approach to Identify Pathological Situations in the Female Menstrual Cycle
Wednesday 15:15-16:40 |
II-23 Ahmed Suleiman
A Modeling and Simulation Framework Characterizing the Time Courses of Adverse Events in Non-Small Cell Lung Cancer Patients Treated with Erlotinib
Wednesday 15:15-16:40 |
II-24 Elin Svensson
Albumin concentrations and body weight in MDR-TB patients over time on treatment and the impact on bedaquiline pharmacokinetics
Wednesday 15:15-16:40 |
II-25 Robin Svensson
Application of the Multistate Tuberculosis Disease Model in Rifampicin Treated Pulmonary Tuberculosis Patients
Wednesday 15:15-16:40 |
II-26 Eva Sverrisdottir
Modelling drug-drug interactions between morphine and methylnaltrexone
Wednesday 15:15-16:40 |
II-27 Maciej Swat
Standardized Output: flexible and tool-independent storage format of typical M&S results
Wednesday 15:15-16:40 |
II-28 Amit Taneja
Translational modelling of prolactin response following administration of D2 antagonists in rats
Wednesday 15:15-16:40 |
II-29 Sonya Chapman
Relative Bioavailability to Describe Variability in Exposure for an Oral Drug: A Population PK Model of Abemaciclib in Cancer Patients
Wednesday 15:15-16:40 |
II-30 Max Taubert
Population pharmacokinetics of linezolid in intensive care patients
Wednesday 15:15-16:40 |
II-31 Paulo Teixeira
Population Pharmacokinetics of Phenobarbital in Children, Adolescents and Young Adults Patients.
Wednesday 15:15-16:40 |
II-32 Donato Teutonico
Development of a Cardio-Vascular Systems Pharmacology Platform
Wednesday 15:15-16:40 |
II-33 Hoai-Thu Thai
Joint modeling of longitudinal tumor burden and time-to-event data to predict survival: application to aflibercept in second line metastatic colorectal cancer
Wednesday 15:15-16:40 |
II-34 Mita Thapar
Eltrombopag population pharmacokinetics-pharmacodynamics and effect on platelet counts following different regimens in Chinese adult patients with chronic primary immune thrombocytopenia
Wednesday 15:15-16:40 |
II-35 Yingying Tian
Physiologically based pharmacokinetic model incorporating genetic polymorphism of CYP2D6 to predict the nonlinear kinetics of paroxetine
Wednesday 15:15-16:40 |
II-36 Melanie Titze
PK/PD modeling of biomarker modulation and tumor growth inhibition by BI 893923, a novel IGF-1 receptor inhibitor
Wednesday 15:15-16:40 |
II-37 Huybrecht T'jollyn
The effect of albumin redistribution on the PK of highly bound drugs: a simulation study using the Simcyp M&S platform
Wednesday 15:15-16:40 |
II-38 Mira Tout
The impact of initial metabolic tumor volume on rituximab pharmacokinetics and clinical response in patients with diffuse large B-cell lymphoma
Wednesday 15:15-16:40 |
II-39 Mirjam Trame
Integrated Data Mining and Systems Pharmacology to Explore the Comparative Safety of Brand-Name and Generic Drugs
Wednesday 15:15-16:40 |
II-40 Nikolaos Tsamandouras
Application of the MCMC Bayesian estimation method in NONMEM in the context of physiologically-based pharmacokinetic modelling.
Wednesday 15:15-16:40 |
II-41 Takayo Ueno
Exposure-Response Analysis for Daclatasvir and Asunaprevir in Japanese Subjects with Hepatitis C Virus Infection
Wednesday 15:15-16:40 |
II-42 Moreno Ursino
Incorporating pharmacokinetic information in phase I studies in small populations
Wednesday 15:15-16:40 |
II-43 Elodie Valade
Plasma and seminal plasma population pharmacokinetics of emtricitabine and tenofovir
Wednesday 15:15-16:40 |
II-44 Pyry Välitalo
Morphine efficacy in mechanically ventilated preterm neonates; an item response theory analysis
Wednesday 15:15-16:40 |
II-45 Sven van Dijkman
Optimal dosing recommendations for combination therapy in epilepsy
Wednesday 15:15-16:40 |
II-46 Anne van Rongen
Population pharmacokinetics of paracetamol and glucuronide, sulphate and CYP2E1 mediated metabolites in morbidly obese patients
Wednesday 15:15-16:40 |
II-47 Fiona Vanobberghen
Population pharmacokinetics of tribendimidine metabolites in adults with Opisthorchis viverrini in Laos
Wednesday 15:15-16:40 |
II-48 Anders Viberg
A Population PK Model for Simeprevir in Healthy Volunteers and Patients
Wednesday 15:15-16:40 |
II-49 Sandra Visser
Translational modelling of regular human insulin pharmacokinetics and glucose dynamics in minipig and dog
Wednesday 15:15-16:40 |
II-50 Swantje Völler
Comparison of current dose-reduction schemes for doxorubicin in young children using a recently developed population pharmacokinetic model
Wednesday 15:15-16:40 |
II-51 Johan Wallin
Overall survival and change in tumor size in squamous NSCLC in relation to Necitumumab exposure
Wednesday 15:15-16:40 |
II-52 Chris Walsh
Use of a physiologically-based pharmacokinetic modelling and simulation approach to rationalise actinomycin D dosing in paediatric oncology
Wednesday 15:15-16:40 |
II-53 Hechuan Wang
An Integrated Pharmacokinetic/Viral Dynamic Model for Daclatasvir/Asunaprevir in Patients with Genotype 1 Chronic Hepatitis C
Wednesday 15:15-16:40 |
II-54 Estelle Watson
The population pharmacokinetics of Compound X following single and multiple intravenous infusions, to healthy subjects and subjects following surgery.
Wednesday 15:15-16:40 |
II-55 Benjamin Weber
New Insights in the Pulmonary Fate of Inhaled Drugs
Wednesday 15:15-16:40 |
II-56 Franziska Weber
Pharmacometric approach to characterize key metabolites of acetaminophen in preterm and term neonates
Wednesday 15:15-16:40 |
II-57 Willi Weber
PK of acetaminophen and its metabolites in preterm and term neonates using relevant external background information in a Bayesian approach with Stan
Wednesday 15:15-16:40 |
II-58 Janak Wedagedera
Towards more Realistic Clinical Trial Simulation: Establishing Inter-Correlations between Several Cytochrome P450 Enzyme Abundances in Human Liver
Wednesday 15:15-16:40 |
II-59 Thomas Wendl
A whole-body physiologically-based pharmacokinetic (PBPK) Model for Itraconazole and its metabolite to predict dynamic drug-drug-interactions
Wednesday 15:15-16:40 |
II-60 Paul Westwood
Population pharmacokinetic meta-analysis of ramucirumab in cancer patients
Wednesday 15:15-16:40 |
II-61 Sebastian Wicha
Evaluation of the delta-method to efficiently compute probability of target attainment of antibiotics
Wednesday 15:15-16:40 |
II-62 Mélanie Wilbaux
Semi-mechanistic model to characterize effects of gastric emptying on glucose absorption profiles in obese and non-obese adults
Wednesday 15:15-16:40 |
II-63 Christian Woloch
Development of a mechanistic PK/PD model to describe drug resistance using data from an in vitro dynamic PK/PD model.
Wednesday 15:15-16:40 |
II-64 Dan Wright
Allopurinol dosing in patients with renal impairment
Wednesday 15:15-16:40 |
II-65 Kehua Wu
Genome-wide interrogation of FEV1 longitudinal model in asthmatic children
Wednesday 15:15-16:40 |
II-67 Christine Xu
Application of physiologically based pharmacokinetic (PBPK) modeling for prediction of complex drug-drug interactions involving induction and inhibition of CYP3A4 by fedratinib
Wednesday 15:15-16:40 |
II-68 Hadzliana Zainal
Concentration-effect relationship of epidermal growth factor receptor inhibitor for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Wednesday 15:15-16:40 |
II-69 Stefano Zamuner
Modelling development for count data: NONMEM vs R
Wednesday 15:15-16:40 |
II-70 Hinojal Zazo Gómez
Dosage regimen evaluation of antiretroviral gold nanoparticles using Monte Carlo Simulation
Wednesday 15:15-16:40 |
II-71 Chiara Zecchin
Modelling change in tumour size, survival and new lesions appearance in patients with ovarian cancer treated with carboplatin monotherapy or in combination with gemcitabine
Wednesday 15:15-16:40 |
II-72 Fan Zhang
Application of a mixture model to lamotrigine XR bioequivalence study
Wednesday 15:15-16:40 |
II-73 Jenny zheng
Could we rely on p values only for characterizing exposure response (ER) relationship by a Cox model for oncology trials?
Wednesday 15:15-16:40 |
II-74 Xuan Zhou
A Systems Pharmacology Model for Predicting Anticoagulant Effects of Rivaroxaban in Healthy Subjects: Assessment of Drug Pharmacokinetic and Binding Kinetic Properties
Wednesday 15:15-16:40 |
II-75 Simon Zhou
Complex absorption affecting terminal half-lives leading to pseudo “flip-flop” pharmacokinetics
Wednesday 15:15-16:40 |
II-76 Rui Zhu
Assessment of correlations between early and late efficacy endpoints to identify potential surrogacy relationships in non-Hodgkin lymphoma: a literature-based meta-analysis of 108 Phase II and Phase III studies
Wednesday 15:15-16:40 |
II-77 Simbarashe Peter Zvada
Population Pharmacokinetics of Efavirenz Among HIV infected South Africans Across Different Age Groups Including Pregnant Women
Wednesday 15:15-16:40 |
